These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 35659797)
1. Concurrent Atopic Dermatitis and Psoriasis Vulgaris: Implications for Targeted Biologic Therapy. Johnson MC; Bowers NL; Strowd LC Cutis; 2022 Feb; 109(2):110-112. PubMed ID: 35659797 [TBL] [Abstract][Full Text] [Related]
2. Use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease. Hren MG; Guenin S; Khattri S J Am Acad Dermatol; 2024 Jul; 91(1):138-140. PubMed ID: 38494153 [No Abstract] [Full Text] [Related]
3. Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis. Balakirski G; Burmann SN; Hofmann SC; Kreuter A J Dermatolog Treat; 2023 Dec; 34(1):2258240. PubMed ID: 37705378 [No Abstract] [Full Text] [Related]
4. Concurrent Atopic Dermatitis and Psoriasis Successfully Treated With Dual Biologic Therapy. Kaszycki MA; Pixley JN; Feldman SR Cutis; 2023 Sep; 112(3):E13-E16. PubMed ID: 37903395 [TBL] [Abstract][Full Text] [Related]
5. Is Exploration of Alternate Immune Pathways Needed in Hidradenitis Suppurativa? A Case of Atopic Dermatitis and Concurrent Hidradenitis Suppurativa Responding to Dupilumab. McCormack S; Tazudeen N; Garden BC Case Rep Dermatol Med; 2023; 2023():5189034. PubMed ID: 37908412 [TBL] [Abstract][Full Text] [Related]
6. So close, and yet so far away: The dichotomy of the specific immune response and inflammation in psoriasis and atopic dermatitis. Schäbitz A; Eyerich K; Garzorz-Stark N J Intern Med; 2021 Jul; 290(1):27-39. PubMed ID: 33428274 [TBL] [Abstract][Full Text] [Related]
7. Dupilumab: A review of its use in the treatment of atopic dermatitis. Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919 [TBL] [Abstract][Full Text] [Related]
8. Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases. Kaufman BP; Alexis AF Curr Allergy Asthma Rep; 2018 Aug; 18(10):55. PubMed ID: 30171358 [TBL] [Abstract][Full Text] [Related]
9. Pustular Psoriasis Appearing Induced by Dupilumab Therapy in a Patient With Atopic Dermatitis. Jia X; Li C; Wu J; Liu Q J Drugs Dermatol; 2022 Mar; 21(3):311-312. PubMed ID: 35254760 [TBL] [Abstract][Full Text] [Related]
15. Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: Report of two cases. Ishiuji Y; Umezawa Y; Asahina A; Fukuta H; Aizawa N; Yanaba K; Nakagawa H J Dermatol; 2018 Jun; 45(6):732-734. PubMed ID: 29569296 [TBL] [Abstract][Full Text] [Related]
16. A Narrative Review of the IL-18 and IL-37 Implications in the Pathogenesis of Atopic Dermatitis and Psoriasis: Prospective Treatment Targets. Rusiñol L; Puig L Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126010 [TBL] [Abstract][Full Text] [Related]
17. Atopic Dermatitis as a Paradoxical Reaction to Secukinumab in a Patient With Plaque Psoriasis. Zundell MP; Gottlieb AB; Stanger R J Drugs Dermatol; 2024 Feb; 23(2):97-99. PubMed ID: 38306127 [TBL] [Abstract][Full Text] [Related]
18. New era of biologic therapeutics in atopic dermatitis. Guttman-Yassky E; Dhingra N; Leung DY Expert Opin Biol Ther; 2013 Apr; 13(4):549-61. PubMed ID: 23323893 [TBL] [Abstract][Full Text] [Related]
19. Development of IL-17A inhibitor-induced atopic dermatitis-like rash in psoriasis patients: Insights into immune shift. Li Q; Li X; Li W; Fan R; Ma Q; Luo X; Jian H; Chen X; Cao C; Zheng W Exp Dermatol; 2024 Jan; 33(1):e14958. PubMed ID: 38009235 [TBL] [Abstract][Full Text] [Related]
20. Case report: Clinical and histopathological characteristics of psoriasiform erythema and Ali K; Wu L; Qiu Y; Li M Front Med (Lausanne); 2022; 9():932766. PubMed ID: 35966849 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]